Organ Dysfunction

Alisertib

Description:

Alisertib is an orally administered small molecule inhibitor of Aurora A kinase. Aurora kinases are involved in cell division and inhibiting them may result in the inhibition of cell proliferation. In this Phase I study Alisertib is administered in patients with advanced solid tumors or relapsed lymphoma with varying degrees of hepatic function.


Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798

Cabazitaxel

Description:

Cabazitaxel is a new taxoid, which promotes tubulin assembly and has shown strong antitumor activity against a broad spectrum of tumor models including those sensitive as well as resistant or refractory to other taxanes such as docetaxel. This is a Phase I safety and pharmacokinetic study of XRP6258 (Cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment.


Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798

Halaven

Description:

Halaven is a synthetic analogue of the marine spong natural product halichondrinB. As an inhibitor of microtubules it blocks the cell division and leads to apoptosis of the cancer cells. In this study Halaven is administered on days 1 and 8 of a 21 day cycle in patients with solid tumors who also have impaired renal function.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798

MLN9708

Description:

MLN9708 is an oral proteasome inhibitor. In this Phase I/Ib study it is administered in patients with relapsed/refractory multiple myeloma and advanced solid tumors who have normal renal function or severe renal impairment.


Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798